JP7271446B2 - Ｈｌａ－ｇ転写物およびアイソフォームおよびそれらの使用 - Google Patents

Ｈｌａ－ｇ転写物およびアイソフォームおよびそれらの使用 Download PDF

Info

Publication number
JP7271446B2
JP7271446B2 JP2019570859A JP2019570859A JP7271446B2 JP 7271446 B2 JP7271446 B2 JP 7271446B2 JP 2019570859 A JP2019570859 A JP 2019570859A JP 2019570859 A JP2019570859 A JP 2019570859A JP 7271446 B2 JP7271446 B2 JP 7271446B2
Authority
JP
Japan
Prior art keywords
hla
seq
exon
protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019570859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530978A5 (enExample
JP2020530978A (ja
Inventor
エドガルド ディー． カロセッラ
ディアナ トロニク－ル・ルー
ジャン－フィリップ デリス
ジェローム ヴラン
フランソワ デグランシャン
ナタリー ルア－フレイス
マウルト ジョエル ル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Original Assignee
Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat à l'Énergie Atomique et Aux Énergies Alternatives filed Critical Commissariat à l'Énergie Atomique et Aux Énergies Alternatives
Publication of JP2020530978A publication Critical patent/JP2020530978A/ja
Publication of JP2020530978A5 publication Critical patent/JP2020530978A5/ja
Application granted granted Critical
Publication of JP7271446B2 publication Critical patent/JP7271446B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019570859A 2017-07-24 2018-07-24 Ｈｌａ－ｇ転写物およびアイソフォームおよびそれらの使用 Active JP7271446B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305986.6 2017-07-24
EP17305986.6A EP3434688A1 (en) 2017-07-24 2017-07-24 Hla-g transcripts and isoforms and their uses
PCT/EP2018/070061 WO2019020641A1 (en) 2017-07-24 2018-07-24 TRANSCRIPTS AND ISOFORMS OF HLA-G AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2020530978A JP2020530978A (ja) 2020-11-05
JP2020530978A5 JP2020530978A5 (enExample) 2021-09-02
JP7271446B2 true JP7271446B2 (ja) 2023-05-11

Family

ID=59772544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570859A Active JP7271446B2 (ja) 2017-07-24 2018-07-24 Ｈｌａ－ｇ転写物およびアイソフォームおよびそれらの使用

Country Status (5)

Country Link
US (1) US11655283B2 (enExample)
EP (2) EP3434688A1 (enExample)
JP (1) JP7271446B2 (enExample)
CN (1) CN110799530A (enExample)
WO (1) WO2019020641A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113528448B (zh) * 2020-04-14 2023-01-24 同济大学 一种人胚胎干细胞的构建方法
CN113278590A (zh) * 2021-04-23 2021-08-20 台州恩泽医疗中心(集团) 表达α1α2结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用
CN113249329A (zh) * 2021-04-23 2021-08-13 台州恩泽医疗中心(集团) 表达α1结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用
GB202111905D0 (en) * 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
US20250297013A1 (en) * 2022-03-25 2025-09-25 Hk Inno.N Corporation Hla-g-specific antibody and use thereof
WO2025101877A1 (en) * 2023-11-08 2025-05-15 The Children's Hospital Of Philadelphia Platform for increasing hla class i antigen presentation utilizing engineered chaperone fusion proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007520428A (ja) 2003-06-30 2007-07-26 コミッサリア　ア　レネルジ　アトミック 血液疾患の治療におけるｈｌａ−ｇの可溶形を含む組成物の使用
WO2007091078A2 (en) 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306913B2 (en) * 2002-12-20 2007-12-11 Applera Corporation Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof
EP2730588A1 (en) * 2012-11-12 2014-05-14 Intelectys Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof
US10702559B2 (en) * 2016-02-09 2020-07-07 The General Hospital Corporation Methods and compositions relating to engineered microbial cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007520428A (ja) 2003-06-30 2007-07-26 コミッサリア　ア　レネルジ　アトミック 血液疾患の治療におけるｈｌａ−ｇの可溶形を含む組成物の使用
WO2007091078A2 (en) 2006-02-10 2007-08-16 Axordia Limited Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g

Also Published As

Publication number Publication date
EP3434688A1 (en) 2019-01-30
US20200148743A1 (en) 2020-05-14
US11655283B2 (en) 2023-05-23
WO2019020641A1 (en) 2019-01-31
JP2020530978A (ja) 2020-11-05
EP3658579A1 (en) 2020-06-03
CN110799530A (zh) 2020-02-14

Similar Documents

Publication Publication Date Title
ES2434945T3 (es) Identificación de antígenos asociados a tumores para el diagnóstico y la terapia
US11655283B2 (en) HLA-G transcripts and isoforms and their uses
JP2007537197A (ja) 腫瘍の診断と治療を目的とした表面会合抗原の同定
ES2847025T3 (es) Productos génicos de expresión diferencial en tumores y su uso
ES2685053T3 (es) Productos génicos de expresión diferencial en tumores y su uso
WO2002012325A2 (en) Suppressor gene
JP2008508861A5 (enExample)
EP3314258B1 (en) Antigenic peptides and uses thereof for diagnosing and treating autism
CN110713544A (zh) 融合基因plekha6-ntrk3及其在lch中的应用
US12428459B2 (en) Protein tag to induce ligand dependent degradation of protein/protein-fusions
WO2025006714A1 (en) Anti-upar car t cells and uses thereof
JPWO2005061704A1 (ja) 癌の予防・治療剤
NUNES Method for diagnosing myeloproliferative chronic myelomonocytic leukemia or unclassified myeloproliferative myelodysplastic neoplasm
US20170254803A1 (en) Method for the detection of antigen presentation
HK40000286A (en) Gene products differentially expressed in tumors and their uses
WO2016042137A1 (en) Method for diagnosing myeloproliferative chronic myelomonocytic leukemia or unclassified myeloproliferative myelodysplastic neoplasm
MX2008003464A (en) Identification of tumor-associated antigens for diagnosis and therapy
HK1165480A1 (zh) 肿瘤内差异表达的基因产物及其应用
HK1165472A (en) In tumours differentially expressed gene products and use of the same
HK1165479A (en) In tumours differentially expressed gene products and use of the same
HK1165482A (en) In tumours differentially expressed gene products and use of the same
HK1165477A (en) In tumours differentially expressed gene products and use of the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230426

R150 Certificate of patent or registration of utility model

Ref document number: 7271446

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250